Pharma BD Deal Intelligence

Amgen Inc. / Horizon Therapeutics plc

2022 · Acquisition/Merger · $27.8B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Amgen acquired Horizon Therapeutics for approximately $27.8 billion ($116.50 per share in cash), gaining a portfolio of rare inflammatory disease medicines led by Tepezza (thyroid eye disease), Krystexxa (chronic refractory gout), and Uplizna (NMOSD). The deal overcame an FTC challenge resolved via consent order in September 2023.

Key facts

Announced Dec 12, 2022
Closed Oct 06, 2023
Deal value $27.8B
Deal type Acquisition/Merger
Therapeutic area Immunology, Metabolic, Neurology, Ophthalmology, Rare Disease
Indications Thyroid Eye Disease, Chronic Refractory Gout, Neuromyelitis Optica Spectrum Disorder
Key assets Tepezza (teprotumumab-trbw), Krystexxa (pegloticase), Uplizna (inebilizumab-cdon), Tavneos (avacopan), Procysbi (cysteamine bitartrate), Actimmune (interferon gamma-1b)
Mechanism Anti-IGF-1R monoclonal antibody, PEGylated uricase enzyme, Anti-CD19 monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals